GT Biopharma Appoints David C. Mun-Gavin to Board of Directors
GT Biopharma, Inc. has announced the appointment of David C. Mun-Gavin to its Board of Directors, bringing a wealth of executive leadership experience and global connections to the table. This move coincides with the company's plans for its first data readout this year for GTBP-3650 and its efforts to expand its NK-engager pipeline into broader indications in 2026. David Mun-Gavin's extensive background in senior executive roles will undoubtedly provide valuable guidance as GT Biopharma navigates its next phase of development.
Key Takeaways:
- GT Biopharma has appointed David C. Mun-Gavin to its Board of Directors, bringing his extensive executive leadership experience to the company.
- Mun-Gavin has served in senior roles at global private banks, including Credit Suisse, Swiss Bank Corporation Investment Banking Ltd., and Bankers Trust International Limited.
- Mun-Gavin has also held management positions, including CEO of the Vanol Group, an international oil trading company.
- The appointment is set to benefit GT Biopharma as it approaches its first data readout this year for GTBP-3650 and prepares to expand its NK-engager pipeline.
- Mun-Gavin is a qualified Chartered Accountant (SA) and has a strong accountancy background, having worked for Goldby, Compton and Mackelvie.
- GT Biopharma is a clinical stage immuno-oncology company focused on developing innovative therapeutics based on its proprietary TriKE(r) natural killer (NK) cell engager platform.
- The company is working towards expanding its pipeline into broader indications in 2026.
Statistics:
- 30+ years of executive leadership experience
- 10+ years of experience in international private banking
- 5+ years as CEO of the Vanol Group, an international oil trading company (exact duration not specified)
Sources:
- GT Biopharma, Inc. news release